Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued to investors on Friday. The firm issued a sell rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also issued reports on CARA. Canaccord Genuity Group lowered shares of Cara Therapeutics from a buy rating to a hold rating and decreased their target price for the company from $10.00 to $1.00 in a research report on Thursday, June 13th. HC Wainwright cut shares of Cara Therapeutics from a buy rating to a neutral rating in a report on Thursday, June 13th. Canaccord Genuity Group reissued a hold rating and set a $1.00 target price (down previously from $10.00) on shares of Cara Therapeutics in a report on Thursday, June 13th. Needham & Company LLC lowered Cara Therapeutics from a buy rating to a hold rating in a research note on Thursday, June 13th. Finally, Stifel Nicolaus cut Cara Therapeutics from a buy rating to a hold rating and lowered their price target for the company from $6.00 to $1.00 in a research report on Thursday, June 13th. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. Based on data from MarketBeat, Cara Therapeutics presently has an average rating of Hold and an average price target of $2.32.

Cara Therapeutics Trading Down 3.4 %

CARA opened at $0.27 on Friday. The business’s 50 day moving average is $0.32 and its 200-day moving average is $0.50. The stock has a market cap of $14.55 million, a PE ratio of -0.12 and a beta of 0.70. Cara Therapeutics has a twelve month low of $0.24 and a twelve month high of $1.68.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. As a group, analysts forecast that Cara Therapeutics will post -1.24 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cara Therapeutics stock. Marquette Asset Management LLC bought a new stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned 0.17% of Cara Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.